12 completed, 4 recruiting, 3 unknown, 2 withdrawn. 11 Not applicable, 2 Phase 1, 2 Phase 2, 2 Phase 4, 1 Phase 3.
Follow Type 2 Diabetes Mellitus in Obese: new trials by email Literature Review of Type 2 Diabetes Mellitus in Obese trials Research Report on Type 2 Diabetes Mellitus in Obese
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lifestyle Intervention to Reduce the Risk of Sarcopenia in Adults With Diabetes & Obesity Treated With Semaglutide Wegovy (2.4 Mg Dose) + exercise & nutrition, Wegovy (2.4 Mg Dose) + usual care - Type 2 Diabetes Mellitus in Obese | Not applicable | Recruiting | Sheba Medical Center | 60 | 2025-05-11 | 2026-07-21 |
| Implementation of a Peer Leader-facilitated Dyadic Intervention CHAI dyad study - Cardiovascular Diseases, Type 2 Diabetes Mellitus in Obese | Not applicable | Completed | Rutgers, The State University of New Jersey | 44 | 2025-03-20 | 2026-09-24 |
| Beta-Cell - Liver Interactions in Situations of Modified Beta-Cell Function Measurement of biomarker - Obesity, Childhood, Type 2 Diabetes Mellitus in Obese | Recruiting | Philippe Klee, MD-PhD | 50 | 2024-11-22 | 2026-05-18 | |
| LCMD for Type 2 Diabetes Remission: Evaluation of Effectiveness and Exploration of Individual Differences Low-Calorie Medicine Diet, Low-Calorie Diet - Type 2 Diabetes Mellitus in Obese, Type 2 Diabetes | Not applicable | Not yet recruiting | Shanghai Municipal Hospital of Traditional Chinese Medicine | 170 | 2024-06-01 | 2024-06-04 |
| Effect of Cryolipolysis on Insulin Resistance Cryolipolysis - Type 2 Diabetes Mellitus in Obese, Cryotherapy Effect | Not applicable | Unknown | Cairo University | 60 | 2023-11-01 | 2024-01-25 |
| Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM Semaglutide, Placebo - Fibrosis, Liver, Type 2 Diabetes Mellitus in Obese | Phase 2 | Active not recruiting | University of California, San Diego | 120 | 2023-07-25 | 2026-07-17 |
| Pioglitazone on Heart Failure in Type-2 Diabetes Mellitus Participants Pioglitazone, Placebo - Type 2 Diabetes Mellitus in Obese, Heart Failure With Preserved Ejection Fraction | Phase 4 | Recruiting | The University of Texas Health Science Center at San Antonio | 78 | 2023-07-10 | 2026-09-22 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes K-757 and K-833, Matching placebo to K-757 and K-833 - Obesity, Type 2 Diabetes Mellitus in Obese | Phase 1 | Completed | Kallyope Inc. | 24 | 2023-03-13 | 2023-10-05 |
| Probiotic Lysate (Postbiotic and Metabiotic) Supplementation for Type 2 Diabetes Patients (DELI_Diab Study) Probiotic lysate (postbiotic and metabiotic), Placebo - Obesity, Obesity, Abdominal | Not applicable | Completed | Bogomolets National Medical University | 55 | 2023-02-01 | 2024-04-03 |
| Brain Health in Youth With Normal Weight, Overweight and Obesity at Risk for Type 2 Diabetes (T2D) Observational - Type2 Diabetes, Type 2 Diabetes Mellitus in Obese | Recruiting | Washington University School of Medicine | 117 | 2022-05-24 | 2025-12-18 | |
| Type 2 Diabetes Mellitus With Obesity and Dyslipidemia Treated by Chinese Herbal Medicine Chinese herb medicine - Type 2 Diabetes Mellitus in Obese, Dyslipidemia Associated With Type II Diabetes Mellitus | Completed | Guang'anmen Hospital of China Academy of Chinese Medical Sciences | 95 | 2021-10-27 | 2023-09-15 | |
| Glucagon-like Peptide-1 Agonism With Very Low Calorie Diets Semaglutide Pen Injector [Ozempic], Very-low Calorie Diet - Type 2 Diabetes Mellitus in Obese | Phase 4 | Unknown | University of Nottingham | 45 | 2021-09-15 | 2022-11-04 |
| The Influence of Physical Activity on the Gut Microbiome of Pre-Diabetic Adults Physical Activity Intervention - Obesity, Overweight | Not applicable | Completed | University of Minnesota | 77 | 2021-07-29 | 2025-06-13 |
| Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution, Placebo 1.5 ml, prefilled pen-injector for subcutaneous injection solution - CKD, Diabetic Kidney Disease | Phase 3 | Terminated | Geisinger Clinic | 15 | 2021-07-23 | 2024-02-09 |
| A Study to Assess 11 Beta-hydroxysteroid Dehydrogenase Type 1 Inhibition in Adipose Tissue by SPI-62 SPI-62, Cortisone-d8 - Type 2 Diabetes Mellitus in Obese, Obesity | Phase 1 | Completed | Sparrow Pharmaceuticals | 12 | 2021-07-23 | 2024-04-22 |
| REmote SUpport for Low-Carbohydrate Treatment of Type 2 Diabetes Low Carbohydrate diet - Type 2 Diabetes Mellitus in Obese | Not applicable | Completed | University of Oxford | 115 | 2021-07-01 | 2026-01-05 |
| Heart Rate Variability-Guided Exercise Training in Type 2 Diabetes Aerobic exercise training - Type 2 Diabetes, Diabetes Mellitus, Type 2 | Not applicable | Withdrawn | University of Illinois at Chicago | 2021-06-01 | 2023-04-18 | |
| Phentermine/Topiramate for Uric Acid Stones Phentermine / Topiramate Oral Product, Citrate Salts, Allopurinol, Diet - Obesity, Uric Acid Stones | Phase 2 | Completed | University of Florida | 19 | 2021-03-31 | 2026-06-15 |
| L-Cell Activity in Small Intestine as Biliopancreatic Loop in Obese Patients With DM2 Submitted to RYGBP Analyze basal expression incretin for immunolabeling and mRNA expression glucagon-like secretion peptide-1 (GLP-1) and peptide YY (PYY 3-36) incretins by L cells. - Severe Obesity, Type 2 Diabetes Mellitus in Obese | Not applicable | Unknown | University of Sao Paulo General Hospital | 20 | 2020-02-05 | 2022-07-11 |
| The Effect of Exenatide on Fasting Bile Acids Exenatide treatment - Type 2 Diabetes Mellitus in Obese | Completed | Beijing Chao Yang Hospital | 38 | 2020-01-05 | 2020-06-11 |
Showing 20 of 24. Sign in to see all of them.
Diabetes Mellitus, Type 2 (10) · Obesity (10) · Motor Activity (3) · Insulin Resistance (2) · Obesity, Morbid (2) · Overweight (2) · Pediatric Obesity (2) · Cardiovascular Diseases (1) · Cognitive Dysfunction (1) · Diabetic Nephropathies (1) · Dyslipidemias (1) · Glucose Intolerance (1) · Hyperlipidemias (1) · Inflammation (1) · Liver Cirrhosis (1)
Nutritional and Metabolic Diseases (16) · Metabolic Diseases (13) · Pathological Conditions, Signs and Symptoms (13) · Body Weight (12) · Glucose Metabolism Disorders (12) · Nutrition Disorders (12) · Overnutrition (12) · Signs and Symptoms (12) · Diabetes Mellitus (11) · Endocrine System Diseases (11) · Overweight (10) · Behavior (3) · Pathologic Processes (3) · Hyperinsulinism (2) · Lipid Metabolism Disorders (2)
semaglutide (4) · Caloric Restriction (2) · Allopurinol (1) · Anti-Inflammatory Agents (1) · Diet (1) · Diet, Carbohydrate-Restricted (1) · Exenatide (1) · Exercise (1) · Exercise Therapy (1) · Glucagon-Like Peptide 1 (1) · Glucocorticoids (1) · Nutritional Status (1) · Peptide YY (1) · Phentermine (1) · Pioglitazone (1)
Beijing Chao Yang Hospital (1) · Beth Israel Deaconess Medical Center (1) · Bogomolets National Medical University (1) · Cairo University (1) · Chinese University of Hong Kong (1) · Geisinger Clinic (1) · Guang'anmen Hospital of China Academy of Chinese Medical Sciences (1) · Kallyope Inc. (1) · Max Healthcare Insititute Limited (1) · Philippe Klee, MD-PhD (1) · Rutgers, The State University of New Jersey (1) · Shanghai Municipal Hospital of Traditional Chinese Medicine (1) · Sheba Medical Center (1) · Sparrow Pharmaceuticals (1) · The University of Texas Health Science Center at San Antonio (1)
United States (11) · China (3) · United Kingdom (2) · Brazil (1) · Egypt (1) · India (1) · Israel (1) · Switzerland (1) · Ukraine (1)
Akram Abd El Aziz, Assist.Prof (1) · Alex R Chang, MD, MS (1) · Benjamin Canales, MD (1) · Boyu Li, PHD (1) · David Katz, PhD (1) · Feng Tao, M.D. (1) · Iskandar Idris (1) · Jiaxing Tian, PhD (1) · Karen T D'Alonzo, PhD (1) · Marco Aurelio Santo, MD Phd (1) · Nazarii Kobyliak, PhD (1) · Paul Aveyard, FRCP (1) · Priscila Costa Estabile, MsC (1) · Ralph A DeFronzo, MD (1)
PMID 32539783, PMID 41240060, PMID 41331050, PMID 41850248, PMID 42158917
P50MD017356 (1), R01DK126826 (1), R21DK122317 (1)